{
    "pmcid": "9063451",
    "qa_pairs": {
        "What characteristic of NbBotI-01 contributes to its high neutralization efficacy?": [
            "Slower dissociation rate",
            "Higher molecular weight",
            "Faster binding kinetics",
            "Lower production cost"
        ],
        "What future direction is suggested for enhancing the therapeutic potential of nanobodies?": [
            "Engineering them into trimeric formats",
            "Increasing their molecular weight",
            "Reducing their binding affinity",
            "Decreasing their tissue penetration"
        ],
        "What is the primary target of the nanobodies developed in the study?": [
            "BotI-like toxin from Buthus occitanus tunetanus scorpion venom",
            "SARS-CoV-2 spike protein",
            "Botulinum toxin",
            "Ricin toxin"
        ],
        "What potential factor was noted in the CDR3 region of NbBotI-01 that contributes to its high affinity?": [
            "Presence of positively charged residues",
            "Increased hydrophobicity",
            "Longer loop length",
            "Presence of negatively charged residues"
        ],
        "Which nanobody demonstrated superior neutralization capacity in the study?": [
            "NbBotI-01",
            "NbBotI-17",
            "NbF12-10",
            "NbBotI-05"
        ]
    }
}